股市必读：海翔药业（002099）1月19日董秘有最新回复

Core Viewpoint - The company, Zhejiang Haixiang Pharmaceutical Co., Ltd., is actively involved in investment activities and has recently made significant moves regarding its employee stock ownership plan and investments in other firms, which may impact investor confidence and stock performance. Group 1: Stock Performance and Market Activity - As of January 19, 2026, Haixiang Pharmaceutical's stock closed at 6.54 yuan, reflecting a 0.31% increase, with a turnover rate of 1.22% and a trading volume of 196,700 shares, amounting to a transaction value of 128 million yuan [1] - On January 19, the net inflow of funds from major investors was 7.80 million yuan, while speculative funds saw a net inflow of 9.57 million yuan, contrasted by a net outflow of 17.37 million yuan from retail investors [2][4] Group 2: Corporate Announcements and Investments - The company announced its participation in establishing the Hangzhou Fuhong Equity Investment Partnership with an investment of 100 million yuan, specifically targeting non-listed shares of Fuhong Hanlin [3] - As of January 19, 2026, the company received notification that Fuhong Hanlin has been registered with the China Securities Regulatory Commission, and some of its shareholders' domestic unlisted shares will be converted to H-shares for listing on the Hong Kong Stock Exchange, pending further regulatory procedures [3][4]